Press Releases 2009
- December 15, 2009
Seattle Genetics and Millennium: The Takeda Oncology Company Announce Strategic Collaboration for Novel Late Stage Lymphoma Program Brentuximab Vedotin (SGN-35)
--Seattle Genetics to receive $60 million upfront payment and retain full commercialization rights to brentuximab vedotin in US and Canada; Takeda Group to commercialize in the rest of the world--
--Seattle Genetics to host conference call December 15, 2009 at 8:30 a.m. Eastern Time-- - December 15, 2009
Takeda and Pfizer to Co-Promote Takeda’s Actos® (pioglitazone HCl) for the Treatment of Type 2 Diabetes in China - December 14, 2009
TAK-085 Entered into Phase 3 Clinical Programs for Treatment of Hypertriglyceridemia in Japan - December 2, 2009
Takeda to Continue Strategic Expansion with Operations in Brazil - November 27, 2009
Takeda Pharmaceutical Company wins major British Council Arts & Business International Award for partnership with the London Symphony Orchestra - November 25, 2009
Takeda Submitted an Application for an Additional Indication for Takepron® Capsules 15 and Takepron® OD Tablet 15 in Japan for new indications regarding Prevention of NSAIDs-Associated Gastric Ulcer/Duodenal Ulcer - November 18, 2009
- Takeda Well-Being Program 2009 – "Giving Children in Long-term Treatment the Energy to Live" - November 18, 2009
TAK-438 Enters Phase II Clinical Trials for the Treatment of Reflux Esophagitis - November 13, 2009
Takeda Selected for Carbon Disclosure Leadership Index 2009 - November 2, 2009
Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity - October 23, 2009
Blister card for Benet® 17.5 mg tablets for the treatment of osteoporosis receives the Good Design Award 2009 and the Japan Packaging Contest Appropriate Packaging Award - October 20, 2009
Takeda Announces Principal Sponsorship of the Yokohama Women's Marathon - October 19, 2009
Approval of an Additional Indication of BASEN®; Prevention of Onset of Type 2 Diabetes in Patients with Impaired Glucose Tolerance - October 1, 2009
Takeda to Establish Four Sales and Marketing Subsidiaries to Expand its Operations in Mexico, Turkey and Five Other Countries in Europe - October 1, 2009
Application Submitted for Additional Indications for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors - September 11, 2009
Millennium Initiates Phase II Trial of Prostate Cancer Compound - September 10, 2009
Takeda Introduces ‘Cisco TelePresence’ (Advanced Videoconferencing System) - September 4, 2009
Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS® (pioglitazone HCl) for the Treatment of Type 2 Diabetes - September 3, 2009
Terumo and Takeda to Co-promote Takeda’s Ethical Narcotic Formulations - September 3, 2009
Initiation of Pivotal Phase III Study with Catena®/Sovrima® (Idebenone) in Duchenne Muscular Dystrophy - August 28, 2009
Takeda Announces Changes in Management of Corporate Communications Dept. and Consumer Healthcare Company - August 28, 2009
Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes - July 27, 2009
Takeda Submits a New Drug Application for a Fixed-Dose Combination Tablet of Actos ® with sulfonylurea in Japan - July 27, 2009
Agreements Concluded for “SELTOUCH ® Pap 70, 140” Transdermal Absorption-type Analgesic and Anti-inflammatory Agent - July 23, 2009
Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS® (pioglitazone HCl) - July 13, 2009
Notice Concerning the Determination of the Items of Stock Options (Stock Acquisition Rights) for Members of the Board of Directors - July 8, 2009
ENBREL to Add Indication of Juvenile Idiopathic Arthritis (JIA) - July 7, 2009
CBP501 Enters Phase II Trials for the Treatment of Non-Small Cell Lung Cancer - July 3, 2009
Takeda to hold the commencement ceremony for Construction of New Research Facilities - June 29, 2009
Takeda Submitted an Application for an Additional Indication of Alogliptin for Combination Therapy with Thiazolidinediones, and a New Drug Application of Fixed-Dose Combination of Alogliptin and Pioglitazone HCl in Japan - June 27, 2009
Takeda Receives FDA Complete Response Letter for Alogliptin, An Investigational Treatment for Type 2 Diabetes - June 25, 2009
Takeda Announces Changes in Board Membership and Management Legal Department - June 25, 2009
Notice Concerning Stock Options (Stock Acquisition Rights) for Members of the Board of Directors - June 23, 2009
Takeda Announces Completion of Tender Offer for All Outstanding Shares of IDM Pharma, Inc. - June 23, 2009
Takeda Establishes "Takeda Global Advisory Board" - June 23, 2009
Takeda's Investigational Compound TAK-536 for Treatment of Hypertension Enters into Phase 3 Clinical Trials in Japan - June 18, 2009
New Dosage Combination of Blopress® and diuretic Launched in First European Market - June 8, 2009
Update on Lu AA21004 clinical development programme in major depressive disorder (MDD) - June 4, 2009
Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filing in Europe - May 26, 2009
Takeda to License Vaccine for Haemophilus Influenzae Type B from Novartis - May 20, 2009
Takeda to renovate its Kyoto Herbal Garden - May 18, 2009
Takeda to Acquire IDM Pharma, Adding Mepact (Mifamurtide), The First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology Franchise - May 14, 2009
FDA Approves ACTOplus met® XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes
First and only oral antidiabetic fixed-dose combination medication approved with the extended-release form of metformin - May 7, 2009
Takeda to Start Sales and Marketing Operation in Portugal - May 7, 2009
Takeda to integrate its two manufacturing operations in Ireland - April 27, 2009
Notice of Retirement of a Legal Representative of the Company - April 23, 2009
Lancet Publishes Phase 3 Clinical Data on Basen® - April 21, 2009
Discontinuation of Development of TAK-379 for Treatment of Diabetes - April 15, 2009
Takeda Participates in the United Nations Global Compact - April 9, 2009
Nature Publishes Pre-clinical Data on an Inhibitor of a Novel Target Discovered by Millennium - March 31, 2009
Takeda to Create Global Centers of Excellence
Reorganization helps Takeda realize globalization vision - March 30, 2009
Takeda Expands its Own Sales and Marketing Operations in Europe - March 30, 2009
Takeda Submitted a New Drug Application in Japan for Fixed Dose Combination of Blopress® and Amlodipine Besylate - March 27, 2009
Takeda Establishes Presence in Canada
Company to be based in Mississauga, Ontario - March 26, 2009
Takeda Submitted an Application for an Additional Indication of “Takepron® Capsules 15” and “Takepron® OD Tablets 15” in Japan for Prevention of Onset of low-dose aspirin related gastric and duodenal ulcer - March 24, 2009
Approval of an Additional Indication for ACTOS® in Japan; Concomitant Therapy with Insulin for Type 2 Diabetes - March 23, 2009
Marketing Authorisation for Prostap® to Transfer Back to Takeda from Wyeth in the UK and Republic of Ireland - March 18, 2009
Takeda Submitted a New Drug Application for Lampion® in Japan for Treatment of secondary eradication of Helicobacter pylori - March 13, 2009
Launch of ECARD® LD and ECARD® HD in Japan
– Fixed dose combination tablet of Blopress® and diuretic for treatment of hypertension – - March 13, 2009
ULORIC® (febuxostat) 40-mg and 80-mg Tablets Now Available for the Chronic Management of Hyperuricemia in Patients with Gout
First new treatment option in 40 years for chronic management of condition - March 6, 2009
Takeda Receives New Information on Alogliptin (SYR-322) NDA - March 3, 2009
Millennium Initiates Two Phase 2 Trials of Novel Aurora A Kinase Inhibitor - February 24, 2009
Approval of an Additional Indication of Combination Therapy of Glufast and Insulin Sensitizer in Japan - February 24, 2009
KAPIDEX™ (dexlansoprazole) delayed release capsules Now Available for the Treatment of GERD - February 20, 2009
Discontinuation of Development of TAK-242 for Severe Sepsis - February 14, 2009
ULORIC® (TMX-67, febuxostat) Receives FDA Approval for the Chronic Management of Hyperuricemia in Patients with Gout - February 12, 2009
Independent Data Monitoring Committee Recommends Resuming Enrollment of Non Squamous Nsclc Patients in the Motesanib MONET1 Trial - February 10, 2009
XOMA and Takeda Expand Collaboration - February 2, 2009
London Symphony Orchestra and Takeda celebrate 20 year partnership with launch of 8th Takeda Global Concert Series - February 2, 2009
Receipt of Takeda’s Attorney’s Fees in Takeda’s Patent case on ACTOS in the U.S. - January 31, 2009
FDA Approves KAPIDEX™ (dexlansoprazole) delayed release capsules for the Treatment of GERD
- First proton pump inhibitor (PPI) with a Dual Delayed Release™ (DDR) formulation - - January 22, 2009
Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
- Simultaneous Studies to Investigate Novel Therapy for Ulcerative Colitis and Crohn’s Disease - - January 21, 2009
New Drug Application Approval for ECARD® HD and ECARD LD in Japan
-Fixed dose combination tablet of Blopress® and diuretic for treatment of hypertension- - January 19, 2009
Review of Febuxostat New Drug Application to Continue after PDUFA Date - January 13, 2009
Appointment of New CEO of Takeda Pharmaceuticals Asia Private Limited